ArticleJournal of intensive care2025
Predictors of and hospital-level variation in intensive care unit readmissions in Japan: a nationwide inpatient database study.
Article in Journal of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insurance-related differences in high-intensity care utilization among older patients with cancer.Frontiers in public health · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIntensive care unit (ICU) readmission is a widely recognized marker of patient outcomes and organizational performance. Early ICU readmission-commonly defined as a return to the ICU within 48 h or 2 full calendar days-has been posited as a quality indicator. However, its appropriateness as a quality indicator remains debatable, and evidence from Japan is limited.
methodsWe conducted a retrospective nationwide cohort study in Japan using data from the Diagnosis Procedure Combination database linked with the Hospital Bed Function Report from 2018 through 2023. Adults who were discharged alive after their initial ICU stay, with available Sequential Organ Failure Assessment (SOFA) scores at ICU admission and discharge were included. The primary outcome was early ICU readmission, defined as readmission to the ICU within ≤ 2 full calendar days after the initial ICU discharge. All ICU readmissions (early and late combined) during the same hospitalization were also assessed. Patient- and hospital-level predictors were evaluated using multilevel logistic regression. Between-hospital variability was quantified using intraclass correlation coefficients (ICC) and median odds ratios (MOR).
resultsOf 552,545 eligible patients across 401 hospitals, 22,112 patients (4.0%) underwent ICU readmission; 4728 patients (0.9%) required early readmission. The temporal distribution lacked an early peak, with 32.8% of readmissions occurring ≥ 14 days and 12.2% occurring ≥ 30 days after the initial ICU discharge. Early readmission was associated with higher Charlson Comorbidity Index values, emergency surgery, and elevated SOFA scores at ICU discharge, particularly residual respiratory and circulatory dysfunction. SOFA scores at ICU admission and ICU stay ≥ 7 days were not predictive of early readmission. Intermediate care transfer conferred protection against early but not overall readmission. Hospital-level variation was substantial (ICC, 14-15%; MOR, approximately 2.0) and persisted after adjusting for patient- and hospital-level factors.
conclusionsIn Japan, early ICU readmissions are less frequent than in most Western countries and often occur long after discharge. Discharge severity scores, rather than disease severity at admission, served as the key predictors of readmission. Persistent unexplained hospital-level variations suggest that the ICU readmission rate alone is insufficient as a standalone indicator of the quality of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.